BetterLife Pharma Inc.

BetterLife Pharma Inc. is a biopharmaceutical company that develops patented pharmaceuticals. The company's primary focus is on BETR-001, a non-hallucinogenic second-generation Lysergic Acid Diethylamide ("LSD") derivative molecule. BETR-001 is designed to mimic the therapeutic potential of LSD for treating conditions like major depressive disorder, anxiety disorder, neuropathic pain, and other neuro-psychiatric and neurological disorders, without causing hallucinations. The active chemical in BETR-001 is 2-bromo-lysergic acid diethylamide ("2-bromo-LSD"), which has been shown in past human clinical trials not to cause hallucinations. BetterLife Pharma Inc. also operates through its subsidiary, MedMelior Inc. ("MedMelior"), which has two products in its development pipeline: MM-001, a topical cream formulation of interferon-alpha 2b, and MM-003, a patent-pending proprietary interferon alpha-2b ("IFNa2b") inhalation formulation. The company utilizes a cost-conscious approach to product research and development, engaging contract development and manufacturing organizations on a fee-for-service basis for necessary research, development, or production. BetterLife Pharma Inc. was incorporated on June 10, 2002, in British Columbia, Canada, and its registered office is located in Vancouver, B.C., Canada.